The 2020 CSCO treatment guidelines for NSCLC (7) recommend bevacizumab combined with chemotherapy for LUAD with an EGFR mutation, which can also provide therapeutic benefits for ccRCC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.